The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Lung Transplant Follow-up & Surveillance

Lifelong multidisciplinary monitoring of lung transplant recipients including immunosuppression management, rejection screening, infection prophylaxis, and chronic lung allograft dysfunction (CLAD) prevention.

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Lung Transplant Follow-up & Surveillance?

Lung transplantation is the definitive therapy for end-stage lung disease (COPD, IPF, cystic fibrosis, PAH, sarcoidosis). Post-transplant survival is improving but median survival remains ~6.7 years for bilateral and ~4.7 years for single lung transplant, limited by chronic rejection and infections. Multidisciplinary care includes pulmonology, transplant surgery, infectious disease, immunology, nephrology, and rehabilitation.

Immunosuppression standard regimen: induction with antithymocyte globulin or basiliximab (some centers); maintenance triple therapy with calcineurin inhibitor (tacrolimus preferred), antimetabolite (mycophenolate mofetil), and corticosteroids. Levels and side effects monitored closely.

Major complications: acute cellular rejection (highest risk first 12 months), antibody-mediated rejection, infection (CMV, EBV, fungal — Aspergillus, bacterial), chronic lung allograft dysfunction (bronchiolitis obliterans syndrome / restrictive allograft syndrome), post-transplant lymphoproliferative disease (PTLD), skin and other malignancies, renal dysfunction from calcineurin inhibitors, diabetes, hypertension, hyperlipidemia, osteoporosis.

Symptoms

Asymptomatic during stable post-transplant phase
Decline in FEV1 (>10% from baseline) — possible rejection or CLAD
Cough, dyspnea, hypoxia — infection or rejection workup
Fever, sputum changes — bacterial pneumonia, CMV, fungal infection
Weight loss, lymphadenopathy — PTLD or malignancy
Edema, hypertension — renal dysfunction or volume overload
Tremor, headache, hair loss, gum hypertrophy — calcineurin inhibitor toxicity
Skin lesions — chronic immunosuppression-related malignancy

Risk Factors

CMV donor/recipient mismatch (D+/R-)
Acute rejection episodes (predict CLAD)
Gastroesophageal reflux (microaspiration drives CLAD)
Respiratory viral infections (community-acquired)
Aspergillus colonization
Antibody development (de novo donor-specific antibodies)
Non-adherence with immunosuppression
Pre-transplant primary disease (CF often higher infection risk)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Decline in spirometry >10% from baseline — urgent transplant team evaluation
  • New cough, dyspnea, fever — infection vs rejection workup
  • Hemoptysis — anastomotic complications or infection
  • Skin lesion concerning for malignancy (BCC, SCC, melanoma)
  • Fatigue, lymphadenopathy, weight loss — PTLD evaluation
  • Medication side effects: tremor, GI upset, renal decline

Treatment Methods

01
Routine surveillance: home spirometry daily, clinic visits every 1–3 months in first year then every 3–6 months, surveillance bronchoscopy with BAL and transbronchial biopsy at 1, 3, 6, 12 months in many centers, then for cause; HRCT chest yearly or as indicated
02
Acute cellular rejection (ISHLT grade A2 or higher): IV pulse methylprednisolone 500–1000 mg × 3 days, oral prednisolone taper; consider photopheresis, antithymocyte globulin, alemtuzumab for refractory rejection
03
Antibody-mediated rejection: plasmapheresis, IVIG, rituximab, bortezomib in severe cases
04
Chronic lung allograft dysfunction (CLAD): subtypes BOS (obstructive), RAS (restrictive), mixed; treatment includes azithromycin (low-dose, 250 mg 3×/week), montelukast, statin, photopheresis, total lymphoid irradiation; lung re-transplantation in selected cases
05
Infection prophylaxis: valganciclovir for CMV (3–12 months based on D/R status), TMP-SMX for Pneumocystis (lifelong), itraconazole/voriconazole/posaconazole for Aspergillus prophylaxis, vaccinations (influenza, pneumococcal, COVID-19, no live vaccines)
06
CMV management: monitor PCR weekly during prophylaxis taper, treat viremia with oral valganciclovir or IV ganciclovir; foscarnet/cidofovir for resistant disease; letermovir prophylaxis option
07
Aspergillus surveillance: galactomannan, BAL culture, chest CT for tracheobronchitis or invasive disease; voriconazole/isavuconazole therapy
08
PTLD monitoring: EBV PCR, biopsy of suspicious lesions, reduce immunosuppression, rituximab, chemotherapy for B-cell PTLD
09
Skin cancer surveillance: dermatology every 6–12 months, sun protection education, treatment of actinic keratoses
10
Renal protection: minimize calcineurin exposure, ACE inhibitor/ARB if proteinuria, transition to belatacept or mTOR inhibitor (sirolimus, everolimus) in selected cases
11
Diabetes, hypertension, hyperlipidemia, osteoporosis management with primary care coordination
12
GERD management: PPI, fundoplication if microaspiration documented and CLAD risk
13
Pulmonary rehabilitation, psychosocial support, return-to-work programs
14
Multidisciplinary clinic: pulmonologist, transplant surgeon, infectious disease, dietitian, pharmacist, social worker, mental health

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.